Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 2
1950 1
1952 10
1953 4
1954 1
1955 2
1956 1
1957 5
1958 1
1960 2
1962 1
1963 2
1965 2
1966 2
1967 2
1968 4
1969 3
1970 4
1971 4
1972 12
1973 14
1974 13
1975 11
1976 11
1977 15
1978 13
1979 11
1980 15
1981 15
1982 14
1983 26
1984 24
1985 23
1986 20
1987 21
1988 35
1989 24
1990 21
1991 23
1992 42
1993 17
1994 27
1995 28
1996 31
1997 28
1998 23
1999 15
2000 19
2001 15
2002 19
2003 19
2004 15
2005 25
2006 18
2007 15
2008 18
2009 12
2010 10
2011 11
2012 18
2013 18
2014 12
2015 11
2016 11
2017 14
2018 12
2019 19
2020 15
2021 19
2022 17
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

961 results

Results by year

Filters applied: . Clear all
Page 1
Intravenous immunoglobulin for patients with unexplained recurrent implantation failure: a 6-year single center retrospective review of clinical outcomes.
Peero EK, Banjar S, Khoudja R, Ton-Leclerc S, Beauchamp C, Benoit J, Beltempo M, Dahan MH, Gold P, Kadoch IJ, Jamal W, Laskin C, Mahutte N, Phillips S, Sylvestre C, Reinblatt S, Mazer BD, Buckett W, Genest G. Peero EK, et al. Among authors: gold p. Sci Rep. 2024 Feb 16;14(1):3876. doi: 10.1038/s41598-024-54423-z. Sci Rep. 2024. PMID: 38365988 Free PMC article.
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Calfa CJ, et al. Among authors: gold pj. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513. JCO Precis Oncol. 2024. PMID: 38354330
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Rohatgi N, et al. Among authors: gold pj. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279. JCO Precis Oncol. 2023. PMID: 38039429
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Duvivier HL, et al. Among authors: gold pj. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10. J Clin Oncol. 2023. PMID: 37561967
Intravenous immunoglobulin use in patients with unexplained recurrent pregnancy loss.
Banjar S, Kadour E, Khoudja R, Ton-Leclerc S, Beauchamp C, Beltempo M, Dahan MH, Gold P, Jacques Kadoch I, Jamal W, Laskin C, Mahutte N, Reinblatt SL, Sylvestre C, Buckett W, Genest G. Banjar S, et al. Among authors: gold p. Am J Reprod Immunol. 2023 Aug;90(2):e13737. doi: 10.1111/aji.13737. Am J Reprod Immunol. 2023. PMID: 37491929
961 results